Technologies for circulating tumor cell separation from whole blood

Petra Bankó, Sun Young Lee, Viola Nagygyörgy, Miklós Zrínyi, Chang Hoon Chae, Dong Hyu Cho, András Telekes, Petra Bankó, Sun Young Lee, Viola Nagygyörgy, Miklós Zrínyi, Chang Hoon Chae, Dong Hyu Cho, András Telekes

Abstract

The importance of early cancer diagnosis and improved cancer therapy has been clear for years and has initiated worldwide research towards new possibilities in the care strategy of patients with cancer using technological innovations. One of the key research fields involves the separation and detection of circulating tumor cells (CTC) because of their suggested important role in early cancer diagnosis and prognosis, namely, providing easy access by a liquid biopsy from blood to identify metastatic cells before clinically detectable metastasis occurs and to study the molecular and genetic profile of these metastatic cells. Provided the opportunity to further progress the development of technology for treating cancer, several CTC technologies have been proposed in recent years by various research groups and companies. Despite their potential role in cancer healthcare, CTC methods are currently mainly used for research purposes, and only a few methods have been accepted for clinical application because of the difficulties caused by CTC heterogeneity, CTC separation from the blood, and a lack of thorough clinical validation. Therefore, the standardization and clinical application of various developed CTC technologies remain important subsequent necessary steps. Because of their suggested future clinical benefits, we focus on describing technologies using whole blood samples without any pretreatment and discuss their advantages, use, and significance. Technologies using whole blood samples utilize size-based, immunoaffinity-based, and density-based methods or combinations of these methods as well as positive and negative enrichment during separation. Although current CTC technologies have not been truly implemented yet, they possess high potential as future clinical diagnostic techniques for the individualized therapy of patients with cancer. Thus, a detailed discussion of the clinical suitability of these new advanced technologies could help prepare clinicians for the future and can be a foundation for technologies that would be used to eliminate CTCs in vivo.

Keywords: CTC; Cancer; Circulating; Separation; Tumor cell; Whole blood.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Different types of whole blood methods where immunocapture and physical selection (size and density) methods are separated into subgroups depending on the main properties of the technique. (“Immunoaffinity,” “Size based,” “Density based,” “Combined” sections; i.c immunocapture)
Fig. 2
Fig. 2
Immunoaffinity-based techniques where the EpCAM antigen is typically targeted on the surface of CTCs for positive enrichment, while the CD45 antigen is targeted on the surface of noncancerous cells for negative enrichment. For positive enrichment, only a subpopulation with a distinct antigen is captured. For negative enrichment, the obtained cancer cells are label-free, and a heterogeneous CTC population is obtained
Fig. 3
Fig. 3
Different CTC membrane microfilters where a an FMSA contains highly porous and flexible micro spring structures in a single layer [32] and b shows a separable bilayer structure where capture is achieved by a gap between the top and bottom porous membranes with 8-μm-diameter holes arranged hexagonally on the bottom layer and larger holes with a diameter of 40 μm on the top layer [33]
Fig. 4
Fig. 4
Microfluidic CTC sorting devices where a Parsortix contains a microscale stepped separation structure (image on the left side) with a cross-sectional gap that gradually decreases the dimension of the fluid path (schematic on the right side) [70, 107] and another microfluidic device and b an MCA contains microcavity arrays with circular- (image on the left side) or rectangular-shaped cavities (image on the right side) [31]

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.
    1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790–801. doi: 10.1016/S1470-2045(12)70211-5.
    1. Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res. 2010;10:283. doi: 10.1186/1472-6963-10-283.
    1. McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009;27:5650–5659. doi: 10.1200/JCO.2009.22.9054.
    1. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008;54:1770–1779. doi: 10.1373/clinchem.2008.110056.
    1. Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17:89–95. doi: 10.1016/j.drup.2014.10.002.
    1. Jameson JL, Longo DL. Precision medicine—personalized, problematic, and promising. Obstet Gynecol Surv. 2015;70:612–614. doi: 10.1097/01.ogx.0000472121.21647.38.
    1. Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747–756. doi: 10.1038/nrc4015.
    1. Vineis P, Matullo G, Manuguerra M. An evolutionary paradigm for carcinogenesis? J Epidemiol Community Health. 2003;57:89–95. doi: 10.1136/jech.57.2.89.
    1. Ashkenazi R, Gentry SN, Jackson TL. Pathways to tumorigenesis--modeling mutation acquisition in stem cells and their progeny. Neoplasia. 2008;10:1170–1182. doi: 10.1593/neo.08572.
    1. Ruddon RW, Holland F, et al. What makes a cancer cell a cancer cell? In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al., editors. Holland-Frei cancer medicine. 6. New York: Academic Press; 2003. pp. 1–29.
    1. Loeb KR, Loeb LA. Significance of multiple mutations in cancer. Carcinogenesis. 2000;21:379–385. doi: 10.1093/carcin/21.3.379.
    1. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–292. doi: 10.1016/j.cell.2011.09.024.
    1. van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: cell invasion and endothelial transmigration. Mutat Res. 2011;728:23–34. doi: 10.1016/j.mrrev.2011.05.002.
    1. Weiss L, Ward PM. Cell detachment and metastasis. Cancer Metastasis Rev. 1983;2:111–127. doi: 10.1007/BF00048965.
    1. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10:8152–8162. doi: 10.1158/1078-0432.CCR-04-1110.
    1. Méhes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001;159:17–20. doi: 10.1016/S0002-9440(10)61667-7.
    1. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, et al. M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010;16:5233–5243. doi: 10.1158/1078-0432.CCR-10-1449.
    1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet Oncol. 1889;133:571–573. doi: 10.1016/S0140-6736(00)49915-0.
    1. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.
    1. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56. doi: 10.1038/35065016.
    1. Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst. 2001;93:1638–1643. doi: 10.1093/jnci/93.21.1638.
    1. Ming Y, Li Y, Xing H, Luo M, Li Z, Chen J, et al. Circulating tumor cells: from theory to nanotechnology-based detection. Front Pharmacol. 2017;8:1–11. doi: 10.3389/fphar.2017.00035.
    1. Esmaeilsabzali H, Beischlag TV, Cox ME, Parameswaran AM, Park EJ. Detection and isolation of circulating tumor cells: principles and methods. Biotechnol Adv. 2013;31:1063–1084. doi: 10.1016/j.biotechadv.2013.08.016.
    1. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol. 2009;6:339–351. doi: 10.1038/nrclinonc.2009.44.
    1. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192:373–382. doi: 10.1083/jcb.201010021.
    1. Bunger S, Zimmermann M, Habermann JK. Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials. Cancer Metastasis Rev. 2015;34:527–545. doi: 10.1007/s10555-015-9582-0.
    1. Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351–365. doi: 10.1177/1758834010378414.
    1. Jin C, McFaul SM, Duffy SP, Deng X, Tavassoli P, Black PC, et al. Technologies for label-free separation of circulating tumor cells: from historical foundations to recent developments. Lab Chip. 2014;14:32–44. doi: 10.1039/C3LC50625H.
    1. Ferreira MM, Ramani VC, Jeffrey SS. Circulating tumor cell technologies. Mol Oncol. 2016;10:374–394. doi: 10.1016/j.molonc.2016.01.007.
    1. Hosokawa M, Yoshikawa T, Negishi R, Yoshino T, Koh Y, Kenmotsu H, et al. Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. Anal Chem. 2013;85:5692–5698. doi: 10.1021/ac400167x.
    1. Yeh Y-T, Harouaka RA, Zheng S-Y. Evaluating a novel dimensional reduction approach for mechanical fractionation of cells using a tandem flexible micro spring array (tFMSA) Lab Chip. 2017;17:691–701. doi: 10.1039/C6LC01527A.
    1. Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, et al. Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells. Sci Rep. 2014;4:7392. doi: 10.1038/srep07392.
    1. Kim TH, Lim M, Park J, Oh JM, Kim H, Jeong H, et al. FAST: Size-selective, clog-free isolation of rare cancer cells from whole blood at a liquid-liquid interface. Anal Chem. 2017;89:1155–1162. doi: 10.1021/acs.analchem.6b03534.
    1. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014;9:694–710. doi: 10.1038/nprot.2014.044.
    1. Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, et al. Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol. 2010;2010:861341. doi: 10.1155/2010/861341.
    1. Mikolajczyk Stephen D., Millar Lisa S., Tsinberg Pavel, Coutts Stephen M., Zomorrodi Maryam, Pham Tam, Bischoff Farideh Z., Pircher Tony J. Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. Journal of Oncology. 2011;2011:1–10. doi: 10.1155/2011/252361.
    1. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011;1:580–586. doi: 10.1158/-11-0215.
    1. Serrano MJ, Ortega FG, Alvarez-Cubero MJ, Nadal R, Sanchez-Rovira P, Salido M, et al. EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget. 2014;5:7486–7497. doi: 10.18632/oncotarget.2217.
    1. Hyun KA, Jung HI. Advances and critical concerns with the microfluidic enrichments of circulating tumor cells. Lab Chip. 2014;14:45–56. doi: 10.1039/C3LC50582K.
    1. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012;7:e33788. doi: 10.1371/journal.pone.0033788.
    1. Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, et al. “Sentinel” circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9:e111597. doi: 10.1371/journal.pone.0111597.
    1. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013;73:2965–2975. doi: 10.1158/0008-5472.CAN-12-4140.
    1. Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. 2014;14:147–156. doi: 10.1039/C3LC51039E.
    1. Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E, et al. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl Oncol. 2015;17:539–546. doi: 10.1007/s12094-015-1275-1.
    1. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat. 2009;118:523–530. doi: 10.1007/s10549-009-0461-7.
    1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897–6904. doi: 10.1158/1078-0432.CCR-04-0378.
    1. Wang L, Balasubramanian P, Chen AP, Kummar S, Evrard YA, Kinders RJ. Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells. Semin Oncol. 2016;43:464–475. doi: 10.1053/j.seminoncol.2016.06.004.
    1. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920–928. doi: 10.1158/1078-0432.CCR-06-1695.
    1. Deng G, Krishnakumar S, Powell AA, Zhang H, Mindrinos MN, Telli ML, et al. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 2014;14:456. doi: 10.1186/1471-2407-14-456.
    1. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 1990;11:231–238. doi: 10.1002/cyto.990110203.
    1. Xiong K, Wei W, Jin Y, Wang S, Zhao D, Wang S, et al. Biomimetic immuno-magnetosomes for high-performance enrichment of circulating tumor cells. Adv Mater. 2016;28:7929–7935. doi: 10.1002/adma.201601643.
    1. Lu N-N, Xie M, Wang J, Lv S-W, Yi J-S, Dong W-G, et al. Biotin-triggered decomposable immunomagnetic beads for capture and release of circulating tumor cells. ACS Appl Mater Interfaces. 2015;7:8817–8826. doi: 10.1021/acsami.5b01397.
    1. Adams AA, Okagbare PI, Feng J, Hupert ML, Patterson D, Gottert J, et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J Am Chem Soc. 2008;130:8633–8641. doi: 10.1021/ja8015022.
    1. Dharmasiri U, Balamurugan S, Adams AA, Okagbare PI, Obubuafo A, Soper SA. Highly efficient capture and enumeration of low abundance prostate cancer cells using prostate-specific membrane antigen aptamers immobilized to a polymeric microfluidic device. Electrophoresis. 2009;30:3289–3300. doi: 10.1002/elps.200900141.
    1. Dharmasiri U, Njoroge SK, Witek MA, Adebiyi MG, Kamande JW, Hupert ML, et al. High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system. Anal Chem. 2011;83:2301–2309. doi: 10.1021/ac103172y.
    1. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–1239. doi: 10.1038/nature06385.
    1. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip. 2010;10:27–29. doi: 10.1039/B917959C.
    1. Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C, et al. Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol. 2013;8:735–741. doi: 10.1038/nnano.2013.194.
    1. Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, et al. Tunable thermal-sensitive polymer–graphene oxide composite for efficient capture and release of viable circulating tumor cells. Adv Mater. 2016;28:4891–4897. doi: 10.1002/adma.201600658.
    1. Teotia AK, Sami H, Kumar A. Thermo-responsive polymers: structure and design of smart materials. In: Zhang Z, editor. Switchable and responsive surfaces and materials for biomedical applications. Oxford: Woodhead Publishing; 2015. pp. 3–43.
    1. Wang S, Liu K, Liu J, Yu ZT, Xu X, Zhao L, et al. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl. 2011;50:3084–3088. doi: 10.1002/anie.201005853.
    1. Park MH, Reategui E, Li W, Tessier SN, Wong KH, Jensen AE, et al. Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchange in a microfluidic chip. J Am Chem Soc. 2017;139:2741–2749. doi: 10.1021/jacs.6b12236.
    1. STEMCELL Technologies. . Accessed 30 Oct 2018.
    1. Gallant JN, Matthew EM, Cheng H, Harouaka R, Lamparella NE, Kunkel M, et al. Predicting therapy response in live tumor cells isolated with the flexible micro spring array device. Cell Cycle. 2013;12:2132–2143. doi: 10.4161/cc.25165.
    1. Ma Y, Hao S, Wang S, Zhao Y, Lim B, Lei M, et al. A combinatory strategy for detection of live ctcs using microfiltration and a new telomerase-selective adenovirus. Mol Cancer Ther. 2015;14:835–843. doi: 10.1158/1535-7163.MCT-14-0693.
    1. Harouaka RA, Zhou MD, Yeh YT, Khan WJ, Das A, Liu X, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem. 2014;60:323–333. doi: 10.1373/clinchem.2013.206805.
    1. Huang T, Jia CP, Jun Y, Sun WJ, Wang WT, Zhang HL, et al. Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip. Biosens Bioelectron. 2014;51:213–218. doi: 10.1016/j.bios.2013.07.044.
    1. Tan SJ, Yobas L, Lee GYH, Ong CN, Lim CT. Microdevice for the isolation and enumeration of cancer cells from blood. Biomed Microdevices. 2009;11:883–892. doi: 10.1007/s10544-009-9305-9.
    1. Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer. 2016;138:2894–2904. doi: 10.1002/ijc.30007.
    1. ANGLE. UK, Guildford, Surrey. GU2 7AF. . Accessed 30 Oct 2018.
    1. Hosokawa M, Hayata T, Fukuda Y, Arakaki A, Yoshino T, Tanaka T, et al. Size-selective microcavity array for rapid and efficient detection of circulating tumor cells. Anal Chem. 2010;82:6629–6635. doi: 10.1021/ac101222x.
    1. Yagi S, Koh Y, Akamatsu H, Kanai K, Hayata A, Tokudome N, et al. Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. PLoS One. 2017;12:e0179744. doi: 10.1371/journal.pone.0179744.
    1. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002;49:150–158. doi: 10.1002/cyto.10161.
    1. Campton DE, Ramirez AB, Nordberg JJ, Drovetto N, Clein AC, Varshavskaya P, et al. High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining. BMC Cancer. 2015;15:360. doi: 10.1186/s12885-015-1383-x.
    1. Fachin F, Spuhler P, Martel-Foley JM, Edd JF, Barber TA, Walsh J, et al. Monolithic chip for high-throughput blood cell depletion to sort rare circulating tumor cells. Sci Rep. 2017;7:10936. doi: 10.1038/s41598-017-11119-x.
    1. Sajay BN, Chang CP, Ahmad H, Khuntontong P, Wong CC, Wang Z, et al. Microfluidic platform for negative enrichment of circulating tumor cells. Biomed Microdevices. 2014;16:537–548. doi: 10.1007/s10544-014-9856-2.
    1. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95:4589–4594. doi: 10.1073/pnas.95.8.4589.
    1. Yang L, Lang JC, Balasubramanian P, Jatana KR, Schuller D, Agrawal A, et al. Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng. 2009;102:521–534. doi: 10.1002/bit.22066.
    1. Lara O, Tong X, Zborowski M, Chalmers JJ. Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol. 2004;32:891–904. doi: 10.1016/j.exphem.2004.07.007.
    1. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–544. doi: 10.1038/nbt.2576.
    1. Pantel K, Deneve E, Nocca D, Coffy A, Vendrell JP, Maudelonde T, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 2012;58:936–940. doi: 10.1373/clinchem.2011.175570.
    1. Cauley CE, Pitman MB, Zhou J, Perkins J, Kuleman B, Liss AS, et al. Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings. J Am Coll Surg. 2015;221:699–707. doi: 10.1016/j.jamcollsurg.2015.05.014.
    1. Franken B, de Groot MR, Mastboom WJ, Vermes I, van der Palen J, Tibbe AG, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res. 2012;14:R133. doi: 10.1186/bcr3333.
    1. Crisan D, Ruark DS, Decker DA, Drevon AM, Dicarlo RG. Detection of circulating epithelial cells after surgery for benign breast disease. Mol Diagn. 2000;5:33–38.
    1. Satelli A, Brownlee Z, Mitra A, Meng QH, Li S. Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem. 2015;61:259–266. doi: 10.1373/clinchem.2014.228122.
    1. Sheng W, Ogunwobi OO, Chen T, Zhang J, George TJ, Liu C, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip. 2014;14:89–98. doi: 10.1039/C3LC51017D.
    1. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A. 2009;106:3970–3975. doi: 10.1073/pnas.0813188106.
    1. Stanford University: Office of technology licensing, . [Last visit: 2018 October 30].
    1. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther. 2012;11:2526–2534. doi: 10.1158/1535-7163.MCT-12-0460.
    1. Pluim D, Devriese LA, Beijnen JH, Schellens JH. Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. Cytometry A. 2012;81:664–671. doi: 10.1002/cyto.a.22049.
    1. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science. 2013;339:971–975. doi: 10.1126/science.1229568.
    1. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366–377. doi: 10.1056/NEJMoa0800668.
    1. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010;107:18392–18397. doi: 10.1073/pnas.1012539107.
    1. Peters CE, Maestre-Battle D, Woodside SM, Thomas TE, Eaves AC. Proceedings of the 107th annual meeting of the american association for cancer research. New Orleans: AACR; 2016. Unbiased enrichment of circulating tumor cells directly from whole blood abstract; p. Abstract nr 511.
    1. Harouaka RA, Nisic M, Zheng SY. Circulating tumor cell enrichment based on physical properties. J Lab Autom. 2013;18:455–468. doi: 10.1177/2211068213494391.
    1. Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, Lim B, et al. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. Oncotarget. 2016;7:3662–3676. doi: 10.18632/oncotarget.6657.
    1. Shen Z, Wu A, Chen X. Current detection technologies for circulating tumor cells. Chem Soc Rev. 2017;46:2038–2056. doi: 10.1039/C6CS00803H.
    1. Coumans FA, van Dalum G, Beck M, Terstappen LW. Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS One. 2013;8:e61770. doi: 10.1371/journal.pone.0061770.
    1. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5:179ra47. doi: 10.1126/scitranslmed.3005616.
    1. Apel P. Track etching technique in membrane technology. Radiat Meas. 2001;34:559–566. doi: 10.1016/S1350-4487(01)00228-1.
    1. Tan SJ, Lakshmi RL, Chen P, Lim WT, Yobas L, Lim CT. Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. Biosens Bioelectron. 2010;26:1701–1705. doi: 10.1016/j.bios.2010.07.054.
    1. Miller MC, Robinson PS, Wagner C, O'Shannessy DJ. The parsortix cell separation system-a versatile liquid biopsy platform. Cytometry A. 2018;93:1234–1239. doi: 10.1002/cyto.a.23571.
    1. Magbanua M, Jesus M, Park JW. Circulating tumor cells methods in molecular biology. New York: Humana Press; 2017.
    1. Cho H, Kim J, Song H, Sohn KY, Jeon M, Han KH. Microfluidic technologies for circulating tumor cell isolation. Analyst. 2018;143:2936–2970. doi: 10.1039/C7AN01979C.
    1. Chudziak J, Burt DJ, Mohan S, Rothwell DG, Mesquita B, Antonello J, et al. Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst. 2016;141:669–678. doi: 10.1039/C5AN02156A.
    1. Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D, et al. Optimization and evaluation of a novel size based circulating tumor cell isolation system. PLoS One. 2015;10:e0138032. doi: 10.1371/journal.pone.0138032.
    1. Yoshino T, Kanbara H, Negishi R, Takai K, Matsunaga T, Tanaka T. Towards single-cell genome analysis of circulating tumor cells based on microcavity array. In: Yoshino T, Kanbara H, Negishi R, Takai K, Matsunaga T, Tanaka T, editors. World automation congress. Rio Grande, Puerto Rico: IEEE; 2016. pp. 1–11.
    1. Negishi R, Hosokawa M, Nakamura S, Kanbara H, Kanetomo M, Kikuhara Y, et al. Development of the automated circulating tumor cell recovery system with microcavity array. Biosens Bioelectron. 2015;67:438–442. doi: 10.1016/j.bios.2014.09.002.
    1. Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, Naito T, et al. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system. PLoS One. 2013;8:e67466. doi: 10.1371/journal.pone.0067466.
    1. Balic M, Dandachi N, Hofmann G, Samonigg H, Loibner H, Obwaller A, et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom. 2005;68:25–30. doi: 10.1002/cyto.b.20065.
    1. Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, et al. Circulating tumor cells in melanoma patients. PLoS One. 2012;7:e41052. doi: 10.1371/journal.pone.0041052.
    1. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010;10:666. doi: 10.1186/1471-2407-10-666.
    1. Kalinich M, Bhan I, Kwan TT, Miyamoto DT, Javaid S, LiCausi JA, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017;114:1123–1128. doi: 10.1073/pnas.1617032114.
    1. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302–6309. doi: 10.1158/1078-0432.CCR-08-0872.
    1. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2013;59:110–118. doi: 10.1373/clinchem.2012.194258.
    1. Zahn H, Steif A, Laks E, Eirew P, VanInsberghe M, Shah SP, et al. Scalable whole-genome single-cell library preparation without preamplification. Nat Methods. 2017;14:167–173. doi: 10.1038/nmeth.4140.
    1. Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the science. Nat Rev Genet. 2016;17:175–188. doi: 10.1038/nrg.2015.16.
    1. Vitak SA, Torkenczy KA, Rosenkrantz JL, Fields AJ, Christiansen L, Wong MH, et al. Sequencing thousands of single-cell genomes with combinatorial indexing. Nat Methods. 2017;14:302–308. doi: 10.1038/nmeth.4154.
    1. Zilionis R, Nainys J, Veres A, Savova V, Zemmour D, Klein AM, et al. Single-cell barcoding and sequencing using droplet microfluidics. Nat Protoc. 2017;12:44–73. doi: 10.1038/nprot.2016.154.
    1. Kim YR, Yoo JK, Jeong CW, Choi JW. Selective killing of circulating tumor cells prevents metastasis and extends survival. J Hemat Oncol. 2018;11:114. doi: 10.1186/s13045-018-0658-5.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever